sever
fever
thrombocytopenia
syndrom
sft
emerg
tickborn
diseas
caus
sft
viru
sftsv
infect
despit
gradual
increas
sft
case
high
mortal
endem
region
specif
viral
therapi
vaccin
avail
develop
singl
recombin
plasmid
dna
encod
sftsv
gene
gn
gc
togeth
npn
fusion
antigen
vaccin
candid
viral
antigen
fuse
fmslike
tyrosin
ligand
gene
incorpor
plasmid
enhanc
cellmedi
immun
vaccin
dna
provid
complet
protect
ifnar
ko
mice
upon
lethal
sftsv
challeng
wherea
immun
plasmid
without
gene
result
partial
protect
sinc
fail
detect
antibodi
surfac
glycoprotein
gn
gc
immun
mice
antigenspecif
cellular
immun
confirm
enhanc
antigenspecif
cell
respons
might
play
major
role
protect
final
evalu
degre
protect
immun
provid
protein
immun
individu
glycoprotein
gn
gc
although
protein
antigen
induc
signific
level
neutral
activ
sftsv
gn
vaccin
result
rel
higher
neutral
activ
better
protect
gc
vaccin
howev
antigen
fail
provid
complet
protect
given
dna
vaccin
fail
induc
suffici
immunogen
human
trial
compar
protein
vaccin
optim
combin
dna
protein
element
proper
select
target
antigen
incorpor
effici
adjuv
need
investig
sftsv
vaccin
develop
sever
fever
thrombocytopenia
syndrom
sft
emerg
tickborn
infecti
diseas
caus
sft
viru
sftsv
belong
phenuivirida
famili
bunyaviral
genom
sftsv
compos
three
segment
rna
larg
l
segment
encod
rnadepend
rna
polymeras
rdrp
medium
encod
envelop
glycoprotein
gngc
small
encod
nucleocapsid
nonstructur
protein
np
ns
clinic
manifest
includ
fever
gastrointestin
symptom
leukocytopenia
thrombocytopenia
diseas
mortal
sft
patient
estim
even
though
major
sft
case
report
china
korea
japan
sftsv
infect
southern
asia
includ
vietnam
recent
report
retrospect
survey
current
specif
viral
therapi
vaccin
avail
effect
vaccin
need
combat
rel
high
mortal
especi
elderli
patient
spread
sftsv
human
vaccin
develop
sft
earli
discoveri
phase
studi
vaccin
candid
use
anim
infect
model
immun
ns
antigen
freund
adjuv
mice
natur
resist
sftsv
partial
mimic
human
infect
fail
enhanc
viral
clearanc
although
induc
high
titer
antin
antibodi
significantli
elev
level
sera
upon
viral
challeng
vaccin
plasmid
dna
encod
np
ns
peptid
also
enhanc
antigenspecif
cellular
immun
cell
secret
cell
balbc
mice
appli
nanopattern
microneedl
howev
protect
effect
cellular
immun
induc
dna
vaccin
confirm
vivo
infect
sftsv
recent
dong
f
et
al
report
singl
dose
live
attenu
recombin
vesicular
stomat
viru
rvsv
vaccin
express
sftsv
gngc
glycoprotein
elicit
high
titer
protect
neutral
antibodi
wild
type
interferon
receptor
knockout
ifnar
ko
mice
clearli
show
singl
dose
rvsv
carri
sftsv
gngc
could
provid
complet
protect
lethal
challeng
sftsv
young
old
ifnar
ko
mice
promis
infect
model
sever
human
infect
sftsv
nevertheless
potenti
role
cellular
immun
viral
antigen
complet
protect
examin
studi
although
adopt
transfer
immun
sera
mice
immun
rvsvgngc
ifnar
ko
mice
provid
partial
protect
lethal
sftsv
challeng
studi
develop
recombin
plasmid
dna
psftsv
encod
extracellular
domain
gn
gc
npn
fusion
antigen
dna
vaccin
candid
examin
whether
could
provid
protect
immun
lethal
sftsv
infect
ifnar
ko
mice
order
facilit
process
present
sftsv
antigen
dendrit
cell
dc
enhanc
antigenspecif
cell
respons
recombin
antigen
fuse
fmslike
tyrosin
ligand
moreov
gener
recombin
dna
encod
addit
recombin
viral
antigen
enhanc
cellmedi
immun
vaccin
provid
complet
protect
ifnar
ko
mice
upon
lethal
sftsv
challeng
wherea
immun
psftsv
elicit
partial
protect
indic
antigenspecif
cellular
immun
respons
enhanc
coexpress
could
play
signific
role
protect
lethal
sftsv
infect
confirm
significantli
higher
level
gn
npspecif
cell
respons
mice
vaccin
compar
mock
vectorimmun
mice
therefor
result
indic
enhanc
antigenspecif
cell
immun
multipl
sftv
antigen
dna
vaccin
could
promis
direct
develop
effect
vaccin
sftsv
infect
anim
experi
conduct
anim
biosafeti
level
facil
seoul
nation
univers
hospit
intern
vaccin
institut
studi
approv
seoul
nation
univers
hospit
intern
vaccin
institut
institut
anim
care
use
committe
snuh
iacuc
ivi
iacuc
conduct
strict
accord
recommend
nation
guidelin
care
use
laboratori
anim
order
gener
plasmid
dna
vaccin
gene
encod
ectodomain
gn
gc
genebank
access
npn
fusion
protein
genebank
access
respect
synthes
genscript
piscataway
nj
usa
clone
vector
genexin
seongnam
republ
korea
gene
fuse
signal
peptid
tissu
plasminogen
activ
tpa
uniport
uniport
nterminu
psftsv
fig
addit
murin
gene
uniport
also
synthes
genscript
clone
psftsv
fig
confirm
express
clone
gene
psftsv
hek
cell
atcc
manassa
va
usa
transfect
psftsv
plasmid
use
polyethylenimin
pei
transfect
method
briefli
plasmid
pei
dilut
optimem
media
gibco
gaithersburg
md
usa
incub
hek
cell
h
incub
media
chang
dulbecco
modifi
eagl
medium
dmem
gibco
contain
fetal
bovin
serum
fb
incub
humidifi
co
atmospher
h
cultur
cell
cultur
supernat
harvest
cell
wash
phosphatebuff
salin
pb
lyse
lysi
buffer
mm
trishcl
ph
mm
nacl
contain
proteas
inhibitor
cocktail
sigmaaldrich
st
loui
mo
usa
lysat
supernat
store
use
quantif
protein
mous
supernat
transfect
cell
human
mous
quantikin
elisa
kit
r
system
minneapoli
mn
usa
use
accord
manufactur
instruct
express
gc
gn
npn
fusion
protein
cultur
supernat
cell
lysat
examin
immunoblot
use
rabbit
antign
gc
novu
biolog
centenni
colorado
usa
np
produc
custom
polyclon
antibodi
product
servic
via
abclon
seoul
republ
korea
antibodi
respect
sampl
separ
polyacrylamid
gel
transfer
onto
pvdf
membran
merck
darmstadt
germani
pvdf
membran
block
pb
contain
tween
pbst
skim
milk
room
temperatur
h
membran
sequenti
incub
primari
secondari
antibodi
conjug
hors
radish
peroxidas
hrp
invitrogen
waltham
usa
membran
visual
use
system
fujifilm
tokyo
japan
gene
encod
np
kasjh
strain
genbank
access
clone
vector
novagen
gibbstown
nj
usa
np
protein
purifi
e
coli
strain
harbor
recombin
plasmid
follow
induct
mm
isopropyl
iptg
h
protein
purifi
use
histrap
hp
histidinetag
protein
column
ge
healthcar
chicago
il
usa
accord
manufactur
instruct
recombin
gn
gc
glycoprotein
fuse
fc
region
human
immunoglobulin
heavi
chain
purifi
previous
describ
briefli
vector
clone
gene
encod
gn
gc
transfect
cell
thermo
fisher
scientif
waltham
usa
use
polyethylenimin
transfect
cell
cultur
freestyl
express
medium
gibco
day
overexpress
recombin
protein
supernat
purifi
akta
start
affin
chromatographi
system
hitrap
mabselect
ge
healthcar
accord
manufactur
instruct
fig
determin
antibodi
titer
specif
gc
gn
np
sera
immun
mice
immunoassay
plate
plate
nunc
rochest
ny
usa
coat
ngwell
purifi
antigen
overnight
histag
gn
gc
recombin
protein
purchas
immun
technolog
co
new
york
ny
usa
histag
np
recombin
protein
purifi
mention
antigen
coat
immunoassay
plate
block
h
room
temperatur
pbst
contain
skim
milk
seriallydilut
serum
sampl
incub
h
room
temperatur
subsequ
detect
use
hrpconjug
goat
antimous
igg
santa
cruz
biotechnolog
santa
cruz
ca
usa
peroxidas
substrat
solut
kpl
gaithersburg
md
usa
ad
develop
color
min
reaction
stop
addit
h
po
solut
absorb
measur
nm
use
micropl
reader
tecan
mannedorf
switzerland
spleen
cell
releas
rpmi
media
gibco
minc
spleen
cell
strainer
bd
bioscienc
san
jose
ca
usa
lysi
red
blood
cell
red
blood
cell
lyse
buffer
hybrimax
sigma
st
loui
mo
usa
splenocyt
cultur
h
rpmi
media
contain
fb
gibco
penicillinstreptomycin
gibco
presenc
purifi
gn
np
antigen
well
vbottom
cultur
plate
nunc
roskild
denmark
intracellular
detect
splenocyt
cellswel
treat
golgiplug
bd
bioscienc
final
h
cell
block
ultrablock
solut
rat
sera
hamster
sera
mous
sera
sigma
bd
pharmingen
franklin
lake
nj
usa
follow
stain
bd
bioscienc
bd
bioscienc
biolegend
san
diego
ca
usa
antibodi
conjug
differ
fluoresc
dye
surfac
stain
splenocyt
fix
permeabil
cytofixcytoperm
kit
bd
bioscienc
incub
antibodi
bd
pharmingen
stain
cell
analyz
cytoflex
flow
cytomet
berkman
coulter
inc
brea
ca
usa
flow
cytometri
data
analyz
use
flowjo
softwar
version
tree
star
ashland
usa
gate
strategi
flow
cytometr
analys
summar
fig
sftsv
genbank
access
isol
korean
sft
patient
propag
vero
cell
atcc
supernat
infect
cell
harvest
infect
store
filter
syring
focusform
unit
ffu
sftsv
determin
plaqu
assay
use
methylcellulos
media
briefli
filter
supernat
serial
dilut
ad
monolay
vero
cell
incub
h
viral
supernat
remov
cell
incub
overlay
media
dmem
supplement
fb
methylcellulos
day
cell
fix
paraformaldehyd
intron
seongnam
republ
korea
methanol
merck
darmstadt
germani
sftsv
foci
detect
use
rabbit
antisft
np
antibodi
abclon
goat
antirabbit
igg
secondari
antibodi
conjug
alkalin
phosphatas
thermo
fisher
scientif
viral
plaqu
visual
incub
nbtbcip
solut
roch
mannheim
germani
evalu
neutral
activ
immun
sera
focu
reduct
neutral
titer
frnt
assay
perform
use
immun
mice
sera
sftsv
multipl
infect
preincub
serial
dilut
sera
mice
h
mixtur
viru
sera
ad
onto
monolay
vero
cell
plate
incub
h
supernat
cell
remov
cell
cultur
overlay
media
day
viral
foci
visual
describ
percentag
focu
reduct
calcul
plaqu
without
antibodi
plaqu
antibodi
plaqu
without
antibodi
x
focu
reduct
neutral
titer
frnt
calcul
nonlinear
regress
analysi
log
inhibitor
versu
normal
respons
method
embed
graphpad
prism
softwar
graphpad
softwar
http
wwwgraphpadcom
six
eightweekold
femal
interferon
receptor
knockout
ifnar
ko
mice
use
immun
challeng
test
hous
maintain
specif
pathogenfre
facil
seoul
nation
univers
colleg
medicin
mice
intramuscularli
immun
electropor
use
orbijector
epi
model
sl
vaxigen
inc
seongnam
republ
korea
hind
leg
three
time
twoweek
interv
purifi
psftsv
pb
use
immun
mice
also
subcutan
immun
gnfc
gcfc
protein
absorb
aluminum
hydroxychlorid
alhydrogel
adjuv
invivogen
hong
kong
mice
sera
collect
immun
mice
one
week
third
immun
determin
level
specif
antibodi
titer
two
week
final
immun
mice
subcutan
challeng
x
ffu
sftsv
bodi
weight
mice
surviv
monitor
surviv
mice
fulli
recov
blood
tissu
mice
collect
indic
time
viral
challeng
appli
viral
quantit
use
qrtpcr
hematolog
analysi
total
rna
extract
plasma
sftsvinfect
mice
use
trizol
ls
reagent
life
technolog
carlsbad
ca
usa
accord
manufactur
instruct
total
rna
revers
transcrib
cdna
use
hisenscript
rh
rt
premix
kit
intron
seongnam
republ
korea
cdna
quantifi
use
taqman
univers
master
mix
appli
biosystem
waltham
usa
qrtpcr
perform
biorad
cfx
connect
realtim
system
biorad
hercul
ca
usa
follow
condit
uracilnglycosylas
incub
min
polymeras
activ
min
denatur
anneal
extens
min
amplif
perform
cycl
fluorogen
signal
measur
annealingextens
step
primer
set
detect
probe
qrtpcr
deriv
np
gene
sftsv
np
forward
np
revers
detect
probe
copi
number
calcul
ratio
respect
standard
control
collect
hematolog
data
anim
euthan
bled
cardiac
punctur
blood
prepar
tube
coat
edta
enzynom
daejeon
republ
korea
prior
evalu
platelet
count
paraformaldehyd
ad
edtaanticoagul
whole
blood
sampl
ratio
inactiv
viru
platelet
count
analyz
use
advia
hematolog
system
siemen
healthim
erlangen
germani
data
analyz
use
graph
pad
prism
softwar
graphpad
softwar
la
jolla
ca
usa
statist
analysi
perform
use
twotail
student
ttest
confid
interv
oneway
analysi
varianc
anova
follow
newmankeul
ttest
comparison
valu
among
differ
group
data
express
mean
standard
deviat
sd
statist
analysi
surviv
rate
perform
use
mantelcox
log
rank
test
pvalu
consid
statist
signific
four
viral
gene
sftsv
clone
vector
express
mammalian
cell
fig
extracellular
domain
viral
glycoprotein
gn
gc
separ
clone
plasmid
vector
control
cmv
promot
ire
sequenc
full
length
viral
np
ns
gene
fuse
linker
peptid
gsgsgsgsgsgra
also
clone
vector
control
rsv
promot
protein
fuse
extracellular
domain
signal
sequenc
tissu
plasminogen
activ
tpa
nterminu
promot
antigen
present
traffick
fusion
protein
previous
describ
addit
plasmid
also
encod
murin
enhanc
antigenspecif
cell
respons
express
secret
viral
antigen
cell
transfect
plasmid
confirm
elisa
immunoblot
analysi
fig
viral
antigen
detect
cell
cultur
supernat
well
cellular
lysat
fig
next
assess
antigenspecif
adapt
immun
viral
antigen
vaccin
ifnar
ko
mice
antibodi
respons
np
antigen
significantli
elev
mean
titer
sd
n
mice
immun
mice
vaccin
mock
vector
psftsv
two
week
third
immun
fig
specif
antibodi
gn
gc
bare
detect
vaccin
group
suggest
dna
vaccin
may
effici
induc
specif
antibodi
gn
gc
produc
np
antibodi
respons
presenc
express
order
character
potenti
differ
qualiti
cellmedi
immun
ifnar
ko
mice
immun
dna
vaccin
analyz
antigenspecif
cell
respons
assess
secret
cell
antigendepend
manner
fig
splenocyt
collect
immun
mice
stimul
gn
np
antigen
cytokineposit
cell
subset
analyz
flow
cytometri
frequenc
cytokineposit
cell
induc
splenocyt
mice
significantli
higher
vectorimmun
mice
even
though
cellular
respons
immun
splenocyt
psftsvvaccin
mice
gener
increas
level
statist
signific
suggest
potent
role
coexpress
enhanc
cellmedi
immun
viral
antigen
sinc
observ
signific
elev
cell
respons
specif
viral
antigen
ifnar
ko
mice
immun
dna
vaccin
test
whether
could
provid
protect
immun
lethal
sftsv
infect
suscept
ifnar
ko
mice
korean
sftsv
isol
examin
inocul
mice
x
x
ffu
fig
upon
infect
mice
gradual
lost
bodi
weight
becam
moribund
third
fifth
day
infect
depend
infect
dose
infect
mice
die
infect
fig
similar
surviv
kinet
previous
report
ifnar
ko
mice
infect
sftsv
strain
indic
korean
sftsv
isol
possess
equival
degre
virul
prior
chines
isol
platelet
count
mice
infect
x
ffu
sftsv
significantli
declin
infect
mean
platelet
volum
infect
mice
significantli
higher
control
anim
fig
suggest
platelet
destruct
activ
platelet
product
simultan
occur
lethal
infect
assess
protect
efficaci
dna
vaccin
group
mice
immun
mock
vector
psftsv
three
time
subcutan
challeng
lethal
dose
ffumous
sftsv
fig
mockimmun
mice
expir
sftsv
infect
contrast
mice
immun
protect
lethal
viral
challeng
mice
vaccin
psftsv
surviv
fig
consist
anim
lost
weight
viral
challeng
recov
thereaft
wherea
decreas
bodi
weight
psftsvimmun
mice
observ
challeng
surviv
mice
gradual
recov
examin
progress
thrombocytopenia
acut
phase
infect
mice
platelet
count
vectorimmun
mice
rapidli
declin
expir
fig
left
panel
howev
platelet
count
margin
decreas
mice
vaccin
psftsv
count
rebound
mice
viral
infect
addit
viral
load
significantli
reduc
plasma
psftsv
mice
compar
vectorimmun
control
infect
notabl
despit
similar
initi
viral
load
copiesml
plasma
viral
challeng
among
mice
group
mice
mean
sd
approxim
five
fifti
time
lower
psftsvvaccin
mice
mean
sd
vectorimmun
mice
mean
sd
respect
sinc
antibodi
respons
viral
glycoprotein
gn
gc
poorli
induc
ifnar
ko
mice
immun
dna
vaccin
investig
potenti
protect
role
neutral
antibodi
gn
gc
protein
immun
protein
antigen
fuse
human
fc
fragment
fig
vaccin
gnfc
gcfc
protein
alum
adjuv
effici
induc
specif
antibodi
immun
antigen
ifnar
ko
mice
level
antibodi
titer
antigen
fairli
similar
mean
titer
sd
n
addit
level
neutral
antibodi
sftsv
immun
sera
mice
immun
either
protein
antigen
significantli
higher
fcimmun
control
assess
focu
reduct
neutral
test
frnt
fig
frnt
titer
immun
sera
mice
immun
gcfc
mean
titer
sd
n
gnfc
mean
titer
sd
n
approxim
five
twenti
fold
higher
fcimmun
mice
mean
titer
sd
n
also
notabl
frnt
titer
gnfc
immun
sera
gener
higher
gcfc
sera
although
differ
statist
signific
final
examin
protect
efficaci
protein
vaccin
lethal
infect
sftsv
fig
control
mice
immun
fc
antigen
die
five
day
infect
wherea
gnfc
immun
mice
protect
lethal
challeng
regain
lost
bodi
weight
interestingli
weight
loss
gcfc
vaccin
mice
delay
observ
infect
wherea
control
mice
lost
weight
infect
even
though
mice
immun
gcfc
succumb
death
surviv
three
day
control
mice
extens
median
surviv
time
statist
signific
p
dna
vaccin
wide
investig
variou
infecti
diseas
especi
target
viral
infect
last
two
decad
although
human
clinic
trial
dna
vaccin
yield
poor
immunogen
less
optim
result
approv
veterinari
vaccin
testimoni
proofofconcept
hope
licens
dna
vaccin
human
use
may
far
away
prepar
manuscript
kwak
je
et
al
report
promis
demonstr
dna
vaccin
lethal
sftsv
infect
oldag
ferret
model
use
five
plasmid
dna
encod
individu
viral
gene
gn
gc
np
ns
rdrp
found
vaccin
old
ferret
mixtur
five
plasmid
complet
protect
ferret
lethal
sftsv
challeng
without
develop
clinic
symptom
system
viremia
addit
adopt
transfer
immun
sera
ferret
immun
two
plasmid
encod
gn
gc
could
perfectli
prevent
system
viremia
sftsv
infect
provid
complet
protect
lethal
challeng
suggest
gngc
may
effect
antigen
induc
protect
immun
also
found
nonenvelop
np
ns
rdrp
specif
cell
respons
also
contribut
protect
sftsv
infect
although
fail
induc
neutral
activ
also
observ
vaccin
plasmid
encod
gn
gc
np
ns
togeth
murin
could
provid
protect
immun
ifnar
ko
mice
lethal
sftsv
challeng
howev
current
dna
vaccin
fail
suppress
initi
system
viremia
weight
loss
fig
might
due
lack
type
interferon
signal
andor
poor
antibodi
respons
gn
gc
glycoprotein
requir
viral
neutral
earli
stage
viral
infect
ineffici
gener
antibodi
gn
gc
might
due
absenc
type
interferon
signal
ifnar
ko
mice
fusion
glycoprotein
result
conform
defect
antigen
andor
dysregul
b
cell
respons
given
immun
gnfc
gcfc
protein
induc
specif
antibodi
ifnar
ko
mice
fig
absenc
type
ifn
signal
might
caus
ineffici
antibodi
gener
instead
may
suppress
specif
antibodi
respons
observ
studi
may
exert
tolerogen
effect
cell
via
dendrit
cell
therebi
promot
b
cell
hyporespons
vivo
howev
underli
mechan
cell
dysregul
still
unclear
nevertheless
significantli
enhanc
cell
respons
fuse
target
antigen
promot
persist
mainten
antigenspecif
cell
vivo
studi
also
observ
signific
enhanc
gn
npspecif
cell
respons
well
cell
presenc
express
fig
correl
well
vaccin
protect
efficaci
mice
infect
lethal
dose
sftsv
potent
effect
antigenspecif
cell
respons
protect
sftsv
infect
consist
result
aforement
ferret
infect
model
studi
includ
neg
control
use
plasmid
encod
alon
sinc
shown
alon
fail
boost
antigenspecif
cellular
immun
final
evalu
degre
protect
immun
provid
individu
glycoprotein
gn
gc
protein
antigen
immun
first
time
fig
sinc
previou
studi
show
vaccin
antigen
retain
live
viral
vector
dna
vaccin
provid
complet
protect
lethal
sftsv
challeng
ifnar
ko
mice
old
ferret
respect
protein
antigen
immunogen
induc
signific
level
neutral
activ
sftsv
although
antign
antibodi
retain
rel
higher
neutral
capac
antigc
antibodi
consist
protect
efficaci
gn
protein
vaccin
rel
higher
gc
protein
immun
vaccin
either
protein
antigen
fail
provid
complet
protect
lethal
sftsv
challeng
gc
vaccin
prolong
surviv
time
infect
mice
gn
antigen
provid
partial
protect
consid
gn
gc
glycoprotein
function
viral
ligand
cellular
receptor
bind
viral
membran
fusion
host
endosom
respect
neutral
antigen
might
requir
complet
block
viral
attach
entri
host
cell
taken
togeth
confirm
antigenspecif
cell
respons
sftsv
induc
dna
vaccin
provid
complet
protect
lethal
viral
challeng
immun
individu
glycoprotein
sftsv
also
confer
partial
protect
immun
given
achil
heel
dna
vaccin
remain
poor
immunogen
human
trial
compar
protein
vaccin
optim
combin
dna
andor
protein
vaccin
proper
select
target
antigen
incorpor
effici
vaccin
adjuv
need
investig
develop
best
sftsv
vaccin
formul
human
applic
